Kangmei Pharmaceutical
Market Cap
CN¥12.2b
Last Updated
2021/01/18 09:03 UTC
Data Sources
Company Financials
Executive Summary
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese medicines in China. More Details
Risk Analysis
Snowflake Analysis
Imperfect balance sheet and overvalued.
Similar Companies
Share Price & News
How has Kangmei Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 600518 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 600518's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
3.0%
600518
-3.2%
CN Pharmaceuticals
-1.2%
CN Market
1 Year Return
-33.7%
600518
25.5%
CN Pharmaceuticals
25.4%
CN Market
Return vs Industry: 600518 underperformed the CN Pharmaceuticals industry which returned 25.5% over the past year.
Return vs Market: 600518 underperformed the CN Market which returned 25.4% over the past year.
Shareholder returns
| 600518 | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.0% | -3.2% | -1.2% |
| 30 Day | -7.9% | -1.6% | 4.7% |
| 90 Day | -27.2% | -1.9% | 6.7% |
| 1 Year | -33.7%-33.7% | 26.8%25.5% | 27.5%25.4% |
| 3 Year | -88.6%-88.8% | 29.2%24.5% | 23.2%17.0% |
| 5 Year | -81.3%-82.0% | 54.5%46.3% | 38.9%29.5% |
Long-Term Price Volatility Vs. Market
How volatile is Kangmei Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Kangmei Pharmaceutical undervalued compared to its fair value and its price relative to the market?
0.8x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 600518's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 600518's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 600518 is unprofitable, so we can't compare its PE Ratio to the CN Pharmaceuticals industry average.
PE vs Market: 600518 is unprofitable, so we can't compare its PE Ratio to the CN market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 600518's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 600518 is good value based on its PB Ratio (0.8x) compared to the CN Pharmaceuticals industry average (2.7x).
Next Steps
Future Growth
How is Kangmei Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
24.8%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kangmei Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of 600518’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Kangmei Pharmaceutical performed over the past 5 years?
-68.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 600518 is currently unprofitable.
Growing Profit Margin: 600518 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 600518 is unprofitable, and losses have increased over the past 5 years at a rate of 68.7% per year.
Accelerating Growth: Unable to compare 600518's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 600518 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).
Return on Equity
High ROE: 600518 has a negative Return on Equity (-38.57%), as it is currently unprofitable.
Next Steps
Financial Health
How is Kangmei Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 600518's short term assets (CN¥45.2B) exceed its short term liabilities (CN¥20.1B).
Long Term Liabilities: 600518's short term assets (CN¥45.2B) exceed its long term liabilities (CN¥23.1B).
Debt to Equity History and Analysis
Debt Level: 600518's debt to equity ratio (174%) is considered high.
Reducing Debt: 600518's debt to equity ratio has increased from 58.5% to 174% over the past 5 years.
Debt Coverage: 600518's debt is not well covered by operating cash flow (1.5%).
Interest Coverage: Insufficient data to determine if 600518's interest payments on its debt are well covered by EBIT.
Balance Sheet
Next Steps
Dividend
What is Kangmei Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 600518's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 600518's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 600518's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 600518's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 600518 is not paying a notable dividend for the CN market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 600518's dividend in 3 years as they are not forecast to pay a notable one for the CN market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.4yrs
Average management tenure
CEO
Guowei Liu
0.25
Tenure
Guowei Liu serves as the General Manager at Kangmei Pharmaceutical Co., Ltd. since October 10, 2020.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman of Board of Directors and Deputy General Manager | 8.67yrs | CN¥714.00k | 1.97% CN¥ 240.6m | |
| Chief Financial Officer | 8.67yrs | CN¥480.50k | no data | |
| Deputy General Manager | no data | CN¥713.80k | no data | |
| Deputy GM & Director | 8.67yrs | CN¥330.50k | no data | |
| Deputy General Manager | 8.67yrs | CN¥713.80k | no data | |
| Deputy General Manager | 5.58yrs | CN¥422.80k | no data | |
| Assistant to the President | 8.67yrs | CN¥716.00k | no data | |
| General Manager | 0.25yr | no data | no data | |
| Deputy General Manager | 1.25yrs | no data | no data | |
| Deputy General Manager | 0.25yr | no data | no data | |
| Assistant to the President | 8.5yrs | CN¥126.80k | no data |
3.4yrs
Average Tenure
Experienced Management: 600518's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman of Board of Directors and Deputy General Manager | 8.67yrs | CN¥714.00k | 1.97% CN¥ 240.6m | |
| Deputy GM & Director | 8.67yrs | CN¥330.50k | no data | |
| Deputy General Manager | 8.67yrs | CN¥713.80k | no data | |
| Independent Director | 8.67yrs | CN¥73.90k | no data | |
| Independent Director | 5.58yrs | CN¥100.80k | no data | |
| Director | no data | CN¥78.50k | no data | |
| Director | 8.67yrs | CN¥359.10k | no data | |
| Independent Director | 6.75yrs | CN¥37.00k | no data | |
| Chairman of Supervisory Committee | 10.58yrs | CN¥143.40k | no data | |
| Independent Director | no data | CN¥70.00k | no data | |
| Independent Director | no data | CN¥70.00k | no data | |
| Chairman of the Board | 0.58yr | no data | no data |
8.7yrs
Average Tenure
Experienced Board: 600518's board of directors are considered experienced (8.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Kangmei Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Kangmei Pharmaceutical Co., Ltd.
- Ticker: 600518
- Exchange: SHSE
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥12.236b
- Shares outstanding: 4.97b
- Website: https://www.kangmei.com.cn
Number of Employees
Location
- Kangmei Pharmaceutical Co., Ltd.
- East side of Jieshen Road
- Liusha
- Puning
- Guangdong Province
- 515300
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 600518 | SHSE (Shanghai Stock Exchange) | Yes | Domestic Shares | CN | CNY | Mar 2001 |
| 600518 | XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect) | Yes | Domestic Shares | CN | CNY | Mar 2001 |
Biography
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese medicines in China. It also offers chemical medicines and food products; and operates hospitals and Chinese medicine pharmacies. The company was ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/18 09:03 |
| End of Day Share Price | 2021/01/18 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.